Roche offers an upbeat two-plus-year look at its anti-TIGIT combo therapy — but will two deaths hurt its chances?

Roche’s Genentech got a leg up in the packed anti-TIGIT race earlier this year when the FDA granted it the first breakthrough designation in the field based on some upbeat mid-stage data in non-small cell lung cancer. Now, looking to keep its lead, the pharma giant is offering a...

Click to view original post